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ABSTRACT
Aims and Objectives: The main aim of the study was to find out the association of serum homocysteine (HCY) in diabetic neuropathy patients.
Methods: All the patients who were diagnosed with Type II diabetes mellitus will be included. Their serum levels of fasting blood sugar, postprandial 
blood sugar, glycated hemoglobin, and associated blood parameters will be assessed. Diabetic neuropathy will be confirmed using nerve conduction 
testing, electromyography, and quantitative sensory testing with clinically correlated. The serum HCY levels will be measured and correlated with 
other blood parameters.
Results: Of 1000 patients, 46 were Type I diabetic and 954 were Type II. The prevalence of neuropathy in diabetic patients was 156. Mean serum HCY 
without diabetic neuropathy was 6.8+2.9 and serum HCY with diabetic neuropathy was 21.6+0.29 and p value was found to be 0.0017. The correlation 
between serum HCY and diabetic neuropathy was found to be 14.5 with p=0.001.
Conclusion: There has been a significant increase of HCY in diabetic patients. It can be clearly seen that elevated serum HCY level has led to some of 
the complications of diabetic neuropathy.
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INTRODUCTION
Diabetes is a disease in which blood glucose levels are too high. In the 
food, we take glucose was present. Insulin a hormone which acts as a 
mediator by helping the glucose gets into cells to give them energy. In 
Type 1 diabetic condition, insulin is of little amount or not produced by 
the pancreas, whereas Type 2 diabetes has a chronic condition affected 
the way the body processes blood sugar.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder [1]. 
High blood sugar, insulin resistance, and relative lack of insulin are a 
few characteristics of type 2 diabetic mellitus. Common symptoms are 
weight loss, frequent uncontrolled urination, and thirst.
Nerve dysfunction occurs in the legs and feet often in uncontrolled diabetic 
patients, which is known as diabetic neuropathy [2,3]. Nerve damage 
occurs in diabetes slowly without any symptoms. In the hands, arms, feet, 
and legs symptoms such as pain, tingling, or numbness occur in fewer. 
Roughly 50% of patients with diabetes suffer from diabetic neuropathy [4].
Homocysteine (HCY) is a common amino acid in blood. Methionine is 
converted to HCY and to cysteine, then finally to protein with the help of 
folic acid or Vitamin B6. Men above the age of 50 have increased in HCY 
levels when compared to women [5].
Structure of HCY [6]
Chemical formula - C4H9NO2S
Reference range
HCY level may vary with the technique used so reference value can also 
be varied. Reference values by age are as follows [7]:
•	 For	the	people	between	0	and	30	years	of	age	Hcy	level:	4.6–8.1	µmol/L
•	 For	 the	 people	 between	 30	 and	 59	 years 	 of 	 age	 Hcy	
level:	6.3–11.2	µmol/L	in	males,	whereas	4–5–7.9	µmol/L	in	females.
•	 For	the	people	>59	years	of	age	Hcy	level:	5.8–11.9	µmol/L.
HCY levels are checked through blood tests. A normal level of HCY 
in	per	 liter	of	blood	 is	approximately	between	4.4	and	10.8	µmol/L.	
Hyperhomocysteinemia is a condition where serum HCY level is above 
15	µmol/L	[8].	When	any	one	of	the	Vitamin	B12, Vitamin B6, and folic 
acid deficiency occurs, plasma HCY levels increase in the body [9].
Especially in the aged, elevation in HCY is common [10]. Endothelial 
cell injury may occur with high level of HCY in the blood, which leads 
to inflammation in the blood vessels, which, in turn, may lead to 
atherogenesis. The risk of stroke, peripheral vascular disease (PVD), 
and venous thromboembolism increases with hyperhomocysteinemia 
in the body [11]. Elevated levels of HCY have increased risk of 
cardiovascular disease (CVD) and arteriosclerosis [12]. High level of 
HCY is also responsible for CVD in adolescents [13]. High serum HCY 
level can develop vascular changes, especially in diabetes [14].
Metabolism of homocysteine
HCY metabolism is at the intersection of two metabolic pathways: 
Remethylation and transsulfuration [15] (Scheme 1).
HCY is biosynthesized from methionine by a multistep process. 
Remethylation is a process where HCY is converted to methionine in 
the presence of the enzyme methionine synthase and transsulfuration 
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is a process where HCY is converted to cystathionine by the presence 
of enzyme cystathionine b-synthase. In the remethylation process of 
homocysteine, Vitamin B12 is required. HCY transsulfuration requires 
Vitamin B6 [16].
Relation between HCY and diabetic neuropathy
For	 the	 diabetic	 patient’s	 serum	 levels	 of	 fasting	 blood	 sugar	 (FBS),	
postprandial blood sugar (PPBS), glycated hemoglobin (HbA1C), and 
associated blood parameters will be assessed [17]. Myocardial risk and 
heart attacks are noted in diabetic patients with dyslipidemia. HbA1C and 
lipid profile test to be monitored every 3 months for the diabetic patients 
to understand and prevent heart attacks [18]. Diabetic neuropathy will 
be confirmed using nerve conduction testing (NCT), electromyography 
(EMG), and quantitative sensory testing with clinically correlated. The 
serum HCY levels will be quantified and correlated with other blood 
parameters. Monitoring serum HCY concentration, as well as folate and 
Vitamin B12 status in T2DM patients, could be used as an indicator for 
assessing microvascular risk in DM [19]. Higher HCY levels are found in 
diabetics who have developed micro-/macro-vascular complications, and 
it is highly correlated with HbA1c and serum thyroglobulin which are also 
indicators	of	poor	diabetic	control	[20].	For	prediction	of	cardiovascular	
risk events in Type II diabetic patients, serum HCY can be independently 
used [21]. Prospective study in the large population would be suitable to 
elucidate the HCY function in the pathogenesis of diabetic neuropathy [22].
Macroangiopathy and nephropathy are mostly noted with elevated 
HCY levels in Type 2 diabetes [23]. HCY is clearly associated with the 
occurrence of diabetic neuropathy [24]. Many researchers ended in their 
study that HCY is more helpful in assessing CVD than cholesterol. HCY is 
a sensitive biomarker for both flat deficiency and CVD [25]. Many studies 
also concluded that the risk of atherosclerosis is higher with the increase 
in HCY level, irrespective of either cholesterol is normal or elevated.
Aim
This study aims to study the clinical correlation of serum HCY and 
diabetic neuropathy.
Objectives
The objectives of this study were as follows:
1. To evaluate the prevalence of diabetic neuropathy.
2. To evaluate the serum HCY levels in all diabetic patients.
METHODS
Study site
This study was conducted at the General Medicine Department of ESI 
Hospital, Ayanavaram.
Sample size
A total of 1000 diabetic patients will be assessed for symptoms 
of diabetic neuropathy. Among them, patient who is given a clear 
diagnosis based on clinical evaluation by the physician is involved in 
the study.
S.S = Z2P (1-P)/C2
Z=1.96, C. I=95%, P=0.5
S.S=384






This was a prospective observational study.
Methods involved
All the patients who were diagnosed with T2DM will be included in the 
study.	Their	 serum	 levels	of	FBS,	PPBS,	HbA1C,	and	associated	blood	
parameters will be assessed. Diabetic neuropathy will be confirmed 
using NCT, EMG, and quantitative sensory testing with clinically 
correlated. The serum HCY levels will be measured and correlated with 
other blood parameters.
Plan of the study
The complete study was planned to be carried out for a period of 
8 months from September 2017 to April 2018.
Scheme 1: Homocysteine metabolism
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Patient selection
Inclusion criteria









•	 Patients	who	 are	diagnosed	with	 cardiac	 disorder,	 stroke,	 and	
Alzheimer’s	disease.
•	 Palliative	patients	are	excluded.
An informed consent has been obtained from all the included patients. 
Patient confidentiality has been maintained throughout this study. The 
work has been approved by the Institutional Ethics Committee VISTAS-
SPS/IEC/V/2017/06.
Statistical analysis
Correlation and regression analysis will be carried out with a confidence 
interval of 95% and p<0.05 is considered statistically significant.
RESULTS
Fig. 1 shows that more male patients participated in a study than 
female, and among 1000 enrolled participants, 634 were male and 366 
were female.
From	 Fig. 2, it can be noticed that there are more diabetic patients 
among	the	age	group	of	50–70	years.
Among 1000 enrolled patients, 46 were of Type I and the rest 954 were 
noticed with Type II diabetic patients. Fig. 3 shows that Type II diabetes 
was more prone than Type I diabetic patients.
Among 1000 enrolled diabetic patients, 156 were found to be with 
neuropathy and 844 without neuropathy. Fig. 4 shows that diabetic 
neuropathy patients are less prevalent when compared to the patients 
without neuropathy.
% Prevalence = Number of patients affected/population
         = 156/1000
         = 15.6
Table 1 shows the baseline characteristics that are analyzed in the 
diabetic patients with and without neuropathy.








p value was found to be 0.001 for Z=14.5
*p<0.001	was	considered	to	be	statistically	significant.
Table 2 shows that age, gender, body mass index (BMI), duration of 
disease, HbA1C%, serum homocysteine, biguanide, and insulin use 
affecting the nerve conduction velocity (NCV).
Fig. 1: Gender distribution
Fig. 2: Age distribution
Fig. 3: Diabetes mellitus type
Table 1: Baseline characteristics
S. No. Parameters DM without neuropathy (n=844) DM with neuropathy (n=156) p
1. Male 584 50 -
2. Age (years) 57.6±3.2 51.6±2.91 0.0527
3. BMI 24.1±2.7 23.2±1.8 0.8217
4. Mean distribution of disease (years) 3.18±1.6 5.71±1.8 0.0439*
5. Mean HbA1C % 6.92±1.8 8.14±1.2 0.0327*
6. Mean serum homocysteine (µmol/l) 6.8±2.9 21.6±0.29 0.0017*
All values are mean±SEM. SEM: Standard error of the mean
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Risk of abnormal NCV increased with age. It was clearly noted that the 
risk of NCV abnormalities in diabetes was high with increased HCY 
levels in the body.
*p<0.001 was considered to be statistically significant.





p value of Z=8.48 was found to be 0.001.
*p<0.001	was	considered	to	be	statistically	significant.
Fig. 5 shows the pattern of NCV abnormalities.
In the current study, in the presence of a total of 156 diabetes with 
neuropathy, NCV was found to be abnormal in 125 patients and 
normal in 31 patients. Among those with abnormal NCV, 32 patients 
were found to have axonopathy, 8 with demyelination pattern, motor 
abnormalities diagnosed in 14, 30 had sensory abnormalities, and 41 
had mixed abnormalities.
DISCUSSION
Diabetic neuropathy is seen in many patients who have uncontrolled 
diabetes. Nerve dysfunction due to high blood glucose levels,  is 
common and complex nowadays in the diabetic patients. Abnormal 
levels of serum HCY involve the development of the diabetic neuropathy 
in Type 2 diabetic patients. Several studies showed possible association 
between HCY and diabetic neuropathy in patients with Type 2 diabetes. 
A study also reports that an HCY level progressively increased with the 
development of diabetic nephropathy [26].
Diabetic peripheral neuropathy may be asymptomatic in 50% of 
cases, which is one of the most important complications of diabetes. 
HCY level in diabetic patients is an important biomarker in assessing 
microvascular	 complications	 [27].	 For	 diabetes,	 screening	 and	
treatment with folic acid to be preferred to control the abnormalities 
of HCY in the body.
Most symptoms are not appearing on the early stage of diabetic 
neuropathy.	For	a	diagnosing	diabetic	neuropathy,	careful	examination	
of the lower limbs is required. Patients with peripheral neuropathy must 
be considered at risk of foot ulceration and must receive preventive 
education and podiatric care. There was a significant increase of HCY 
in diabetic patients and its positive significant correlations with BMI, 
HbA1c, glucose, triglyceride, urea, and creatinine [28].
CONCLUSION
Our study reveals that there was a definite relationship between 
elevated serum HCY and diabetic neuropathy. There has been a 
significant increase of HCY in diabetic patients and its positive 
significant correlations with BMI, HbA1c, and duration of disease. It can 
be clearly seen that elevated serum HCY level has led to some of the 
complications of diabetic neuropathy. Hence, we conclude that there 
should be a regularized screening of serum HCY levels in all diabetes, to 
prevent complications of diabetic neuropathy.
Hyperhomocysteinemia was an independent risk factor for 
the occurrence of diabetic neuropathy. Treatment of existing 
hyperhomocysteinemia with folic acid and Vitamin B12 may be useful 
in reducing the risk of microvascular complications in T2DM.
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